Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report

A 61‐year‐old woman with stage IVA lung adenocarcinoma exhibited high PD‐L1 expression. Pembrolizumab was administered as second‐line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three to five courses. She was subsequently di...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Edahiro, Ryuya, Ishijima, Mikako, Kurebe, Hiroyuki, Nishida, Kohei, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Mori, Masahide
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons Australia, Ltd 2019
Matèries:
Case Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6500988/
https://ncbi.nlm.nih.gov/pubmed/30964601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13065
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars